A Collaborative Practice Agreement (CPA) is a legal document in the United States that establishes a legal relationship between clinical pharmacists and cooperating physicians, which allows pharmacists to participate in the collaborative management of drug therapy (CDTM). In 2015, the American College of Clinical Pharmacy (ACCP) published an updated white paper on the management of collaborative drug therapy. CacP regularly publishes updates on this topic, with previous publications in 2003 and 1997. The document describes the recent history of CPAs, legislative advances and discussed payment models for collaborative drug therapy management activities.  According to the PPAC, the certified pharmacist-clinician is authorized to register for a personal DeK number (Drug Enforcement Administration). His field of activity is mainly general medicine and therapeutics. Currently, they have a normative authority for these three types of disease status: high cholesterol, diabetes and hypertension in specific disease management protocols.  Arizona`s CPAs apply to pharmacists and individual practitioners designated by law as « providers. » Providers include established doctors or nurses. The CPA must indicate the conditions of the disease, the medications, the conditions of notification of the supplier and the laboratory tests that the pharmacist can order.
Pharmacists may monitor or modify a patient`s drug treatment in accordance with CPA, provided that the provider and pharmacist have a reciprocal patient-practitioner relationship with the patient.  That our WADA develop standard state legislation to deal with the extension of the practice of pharmacists that considers itself inappropriate or constitutes the practice of medicine, including, but not limited to the issue of the interpretation or application of independent practices, without adequate medical supervision, and to cooperate with interested states and specialties to advance this legislation (Action Directive).  Arkansan`s CPAs apply to individual pharmacists, practitioners admitted as « authorized practitioners to prescribe drugs » and patients. The specific disease stipulates that pharmacists administer, with indicated medications that the pharmacist can use are necessary. Pharmacists are required to document their interventions for discussion with the collaborative practitioner and must keep these records for at least 2 years after the date of registration.  Advanced pharmacy services under a CPA are described as collaborative management of drug therapy (CDTM). [a] While traditional practice for pharmacists provides that the legal authority recognizes drug-related problems (DOP) and proposes solutions for PDs to prescription persons (e.g. B physicians), pharmacists who offer CDTMs solve PDs directly when they recognize them. This may include prescribing activities to select and initiate drugs for the treatment of a patient`s diagnosed diseases (as described in the CPA), stopping the use of prescription or over-the-counter drugs, modifying a patient`s drug treatment (e.g.B.